Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06048133 · ClinicalTrials.gov registry record · Phase 2
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
A Phase 2 study of Cholangiocarcinoma and Bile Duct Cancer, sponsored by Nataliya Uboha.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 4
- Study locations
NCT06048133: Recruiting Phase 2 study of Cholangiocarcinoma and Bile Duct Cancer, sponsored by Nataliya Uboha.
NCT06048133 is a Phase 2 study of Cholangiocarcinoma and Bile Duct Cancer that is actively recruiting participants, run by Nataliya Uboha. The registered enrollment target is 33 participants, below the 385-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06048133, a Phase 2 study of Cholangiocarcinoma and Bile Duct Cancer, is actively recruiting participants, sponsored by Nataliya Uboha.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will include a safety run-in involving 6 study participants. The goal of the safety run-in is to screen for early safety signals of the proposed drug combination. Trial enrollment can continue while full safety assessment is being completed for the first 6 subjects. Participants will receive 4 cycles of combination therapy as described. After 4 cycles (\~6 months), cisplatin will be discontinued, while gemcitabine, zimberelimab (AB122), and quemliclustat (AB680) will be continued. Subjects will be treated until disease progression or development of intolerable toxicities. In total, there will be up to 39 participants on the study.
Primary Outcome
Progression free survival (PFS), as determined by RECIST v1.1, is defined as the time from study registration to the date of documented disease progression or death from any cause.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Zimberelimab
- DRUG Quemliclustat
Study Locations (4)
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Michigan
- University of Michigan Health System - Ann Arbor
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-03-08 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
What NCT06048133 shows while recruiting
NCT06048133 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 385-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Cisplatin is the first listed.
NCT06048133 reports a single indexed study location in Indiana, Michigan, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06048133 about?
NCT06048133 is a clinical study titled "Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)". This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will include a safety run-in involving 6 study participants. The goal of the safety run-in is to screen for early safety signal...
What is the current status of trial NCT06048133?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2024-03-08. Estimated completion is 2027-07.
What conditions does trial NCT06048133 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Bile Duct Cancer, Biliary Tract Carcinoma.
What interventions are being tested in trial NCT06048133?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Zimberelimab (DRUG), Quemliclustat (DRUG).
Who is sponsoring clinical trial NCT06048133?
This trial is sponsored by Nataliya Uboha, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06048133 being conducted?
This trial has 4 study locations across Indiana, Michigan, New Jersey, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06048133's enrollment target sits among peer trials
33 49th of 60 higher than 12 of 60 other Cholangiocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cholangiocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RECRUITING · Phase 2
-
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
RECRUITING · Phase 2
-
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
RECRUITING · Phase 2
-
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI